Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 37Other hematologic neoplasm 19Gastrointestinal 3Thoracic 2Plasma cell 2Genitourinary 2Breast 2CNS 1

Conditions

Carcinoma, Renal Cell 2

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × ibrutinib × Genitourinary × Clear all
NCT02899078 2025-05-18

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

University of California, Davis

Phase 1/2 Completed
31 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT02599324 2023-11-18

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Pharmacyclics LLC.

Phase 1/2 Completed
263 enrolled 34 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡